GtoPdb is requesting financial support from commercial users. Please see our sustainability page for more information.

edonentan   Click here for help

GtoPdb Ligand ID: 13015

Synonyms: BMS-207940 | BMS207940 | compound 16a [PMID: 12502366]
Compound class: Synthetic organic
Comment: Edonentan (BMS-207940) is a selective antagonist of the endothelin receptor A [3,5]. It is a structural analogue of BMS-193884. ETA antagonists induce vasodilation and cardiac inhibition. Edonentan's pharmacodynamics supported oral administration.

A patent review (May 2026) reveals that Perfuse Therapeutics have claimed use of edonentan (or other endothelin receptor antagonists e.g. A-182086) in an intravitreal sustained release implant to reduce elevated endothelin-1 signalling in eye diseases such as glaucoma, dry AMD/geographic atrophy and diabetic retinopathy [1-2,4].
Click here for help

Ligand Activity Visualisation Charts

These are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts.

✖

View interactive charts of activity data across species

edonentan is commercially available from our sponsors

2D Structure
Click here for help

2D Structure

An image of the ligand's 2D structure. For small molecules with SMILES these are drawn using the NCI/CADD Chemical Identifier Resolver. Click on the image to access the chemical structure search tool with the ligand pre-loaded in the structure editor. For other types of ligands, e.g. longer nucleotides and peptides, a manually drawn representation of the molecule may be provided.

✖
Click here for structure editor
Physico-chemical Properties
Click here for help

Physico-chemical Properties

Calculated molecular properties are available for small molecules and natural products (not peptides). Properties were generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/). All properties were selected to enable the prediction of the Lipinski Rule-of-Five profile or ‘druglikeness’ for each ligand. For more info on each category see the help pages.

✖
Hydrogen bond acceptors 7
Hydrogen bond donors 1
Rotatable bonds 10
Topological polar surface area 118.04
Molecular weight 536.64
XLogP 3.05
No. Lipinski's rules broken 1

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)
SMILES / InChI / InChIKey
Click here for help

SMILES / InChI / InChIKey

SMILES (Simplified Molecular Input Line Entry Specification) A specification for unambiguously describing the structure of chemical molecules using short ASCII strings. Canonical SMILES specify a unique representation of the 2D structure without chiral or isotopic specifications. Isomeric SMILES include chiral specification and isotopes.

Standard InChI (IUPAC International Chemical Identifier) and InChIKey InChI is a non-proprietary, standard, textual identifier for chemical substances designed to facilitate linking of information and database searching. An InChIKey is a simplified version of a full InChI, designed for easier web searching.

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)

✖
Canonical SMILES CC1=C(C)ON=C1NS(=O)(=O)C2=C(C=CC=C2)C3=C(C=C(C=C3)C4=NC=CO4)CN(C)C(=O)CC(C)(C)C
Isomeric SMILES CC1=C(ON=C1NS(=O)(=O)C2=CC=CC=C2C3=C(C=C(C=C3)C4=NC=CO4)CN(C)C(=O)CC(C)(C)C)C
InChI InChI=1S/C28H32N4O5S/c1-18-19(2)37-30-26(18)31-38(34,35)24-10-8-7-9-23(24)22-12-11-20(27-29-13-14-36-27)15-21(22)17-32(6)25(33)16-28(3,4)5/h7-15H,16-17H2,1-6H3,(H,30,31)
InChI Key ORJRYNKVKJAJPY-UHFFFAOYSA-N

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)
References
1. Gurkan S, Floyd D. (2026)
Treatment of diabetic retinopathy using endothelin receptor antagonists.
Patent number: US20260076948A1. Assignee: Perfuse Therapeutics Inc. Priority date: 21/11/2025. Publication date: 19/03/2026.
2. Gurkan S, Floyd D, Ding Z. (2024)
Compositions for treatment of ocular diseases.
Patent number: US11873279B2. Assignee: Perfuse Therapeutics Inc. Priority date: 02/08/2022. Publication date: 16/01/2024.
3. Hulpke-Wette M, Buchhorn R. (2002)
BMS-193884 and BMS-207940 Bristol-Myers Squibb.
Curr Opin Investig Drugs, 3 (7): 1057-61. [PMID:12186267]
4. Lin CW, Glendenning AD, Gurkan S. (2022)
Pharmaceutical compositions and intravitreal drug delivery systems for the treatment of ocular diseases.
Patent number: WO2022232588A1. Assignee: Perfuse Therapeutics Inc. Priority date: 29/04/2022. Publication date: 03/11/2022.
5. Murugesan N, Gu Z, Spergel S, Young M, Chen P, Mathur A, Leith L, Hermsmeier M, Liu EC, Zhang R et al.. (2003)
Biphenylsulfonamide endothelin receptor antagonists. 4. Discovery of N-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl]-4-(2-oxazolyl)[1,1'-biphenyl]- 2-yl]methyl]-N,3,3-trimethylbutanamide (BMS-207940), a highly potent and orally active ET(A) selective antagonist.
J Med Chem, 46 (1): 125-37. [PMID:12502366]